Sõpruse pst, 10615, Tallinn, Estonia +372-55650441
  1. Home
  2. Blog
Add Blog Entry RSS

Announcements

No announcements yet

New blog posts

54 Scopus-indexed documents in three years
54 Scopus-indexed documents in three years

30 October, 2026 by Charlotte Lee

Over the past three years, TULTECH’s research...

One Bad Trial, One Big Problem: How a Flawed Study Skewed Prozac Guidance for Children
One Bad Trial, One Big Problem: How a Flawed Study Skewed Prozac Guidance for Children

5 October, 2026 by Mehrdad Fathi

A single small clinical trial from 2006 may...

Can Pancreatic Cancer Be Stopped in Its Tracks? A Radical Tactic Raises Hopes
Can Pancreatic Cancer Be Stopped in Its Tracks? A Radical Tactic Raises Hopes

4 October, 2026 by Mehrdad Fathi

With prospects for new treatments at an...

View all blog entries →

Journals

 

 

Weather

Clouds

8°C

Clouds in Tallinn

Calendar of Events

Closest Events
All events on this day

Blog

Broken Bones, Modified Cells: A Small Trial With Large Implications

Broken Bones, Modified Cells: A Small Trial With Large Implications

aging bone marrow bone regeneration cell therapy fracture prevention fucosylation mesenchymal stromal cells MSC therapy osteoporosis women’s health

Posted on 15 September, 2026 by Mehrdad Fathi

Osteoporosis is one of the most common conditions in aging medicine, and one of the most consequential. Affecting an estimated 200 million women worldwide, it progressively weakens bone architecture until fractures become almost routine — after a stumble, a cough, a minor fall. Existing drug therapies slow that deterioration, but they do not rebuild what has been lost. A small clinical trial published today in Cell suggests that a one-time infusion of modified bone-marrow cells may do...
The Sweetener Question: What the Sucralose-DNA Story Actually Shows

The Sweetener Question: What the Sucralose-DNA Story Actually Shows

DNA damage food additives food safety nutrition science Splenda sucralose sweetener safety

Posted on 14 September, 2026 by Mehrdad Fathi

Few stories in nutrition science travel as fast as one connecting a common food additive to DNA damage. When a 2023 study reported that a chemical linked to sucralose — the sweetener in Splenda — broke DNA strands in human cells, it moved quickly through health media. Three years later, the full picture is considerably more complicated, and considerably more instructive about how laboratory findings translate, or fail to translate, into actual risk. The Chemical at the Center The...
A Virtual Cell That Predicts Your Cancer Treatment

A Virtual Cell That Predicts Your Cancer Treatment

AI drug prediction cancer treatment computational oncology personalized oncology proteomics TNBC triple-negative breast cancer

Posted on 13 September, 2026 by Mehrdad Fathi

One of the persistent frustrations in oncology is this: two patients with the same cancer diagnosis, the same staging, even the same tumor type, can respond completely differently to the same drug. For triple-negative breast cancer, that frustration is acute. TNBC lacks the hormone and HER2 receptors that most targeted therapies exploit, leaving clinicians with a narrower toolkit and fewer molecular handles to guide treatment decisions. A study published in Nature on September 9...
From Undruggable to Unstoppable: How Daraxonrasib Is Rewriting the RAS Story

From Undruggable to Unstoppable: How Daraxonrasib Is Rewriting the RAS Story

cancer treatment 2026 daraxonrasib FDA approval immunotherapy adjacent oncology pancreatic cancer Revolution Medicines targeted therapy

Posted on 9 September, 2026 by Mehrdad Fathi

For decades, RAS proteins occupied a peculiar position in oncology: among the most commonly mutated drivers of cancer, yet effectively out of reach for targeted therapy. That designation — “undruggable” — is now being dismantled at pace. Just one week after the US FDA granted approval to daraxonrasib (Rasonque) for advanced pancreatic cancer, new data published in the New England Journal of Medicine on September 2 show the same drug shrinking tumours in more than 30% of participants...
Cancer Cases Could Surge 67% Worldwide by 2050

Cancer Cases Could Surge 67% Worldwide by 2050

cancer incidence cancer prevention cancer statistics global oncology GLOBOCAN 2024 life sciences oncology public health WHO

Posted on 8 September, 2026 by Mehrdad Fathi

The numbers are stark. In 2024, nearly 21 million people were diagnosed with cancer globally, and 9.8 million died from the disease. Now cases will reach 34 million by 2050 — a 67% increase driven almost entirely by population growth and aging, before any changes in risk factor exposure are factored in. For anyone working at the intersection of oncology, public health, or life sciences, this report lands as both a warning and a challenge. The Scale and Its Drivers The findings are...
  • Page 3 / 9
  • 1
  • 2
  • 3
  • 4
  • 5

Event Categories

0 Conference 0 Symposium 4 Workshop

Past Events

Workshop on Artificial Intelligence Applications in Smart Cities
20 August, 2024
Workshop on Advanced Water Treatment Processes
10 July, 2024
Workshop On Solar System Simulations and Green Buildings
10 May, 2024
Workshop on Water Recycling Simulation and Modelling
15 March, 2024

Today In History

Here are some interesting facts ih history happened on 2 November.

  1. Cobblestone paving of Washington St between Dupont & Kearny starts
  2. North Dakota becomes 39th and South Dakota becomes the 40th state
  3. Lansing-Ishii Agreement
  4. The Balfour Declaration calls for a Jewish homeland
  5. KDKA (Pittsburgh) on the air as 1st commercial radio station
  6. Howard Hughes' Spruce Goose flies for 1st (& last) time
  7. Truman beats Dewey confounding pollsters and newspapers
  8. JS Thurmond 1st senator elected by write-in vote - SC
  9. 1st titanium mill opened Toronto Ohio
  10. Charles Van Doren confesses 21 was fixed
  11. CBS purchases NY Yanks
  12. Ed Giacomin return to Mad Sq Garden as a Red Wing beats Rangers 6-4
  13. Crew of Soyuz 29 returns to Earth aboard Soyuz 31
  14. Edith Bunker dies

Menu

About TULTECH

TULTECH (Talent under Liberty in Technology) is a non-profit organization dedicated to advancing education, research, knowledge, and responsible technological innovation for the benefit of society. Through research, academic publishing, educational activities, events, and technology development, we connect researchers, educators, students, and communities to share knowledge and create practical solutions to social, environmental, and technological challenges.

Mission

Our mission is to advance education, research, knowledge, and technological innovation for the benefit of society. Through research, publications, educational activities, events, and open technological solutions, TULTECH promotes accessible learning, interdisciplinary collaboration, social and environmental responsibility, and the responsible use of technology to create positive impact in communities.

Vision

TULTECH envisions a globally connected society where education, research, and technology are accessible and used responsibly to address social, environmental, and technological challenges. We aspire to contribute to a more inclusive, sustainable, knowledgeable, and innovative future.

 

Talent under Liberty in Technology (TULTECH):  EE472200221072318428